CD274 and breast carcinoma: In mesenchymal breast cancer cells, CMTM6 silencing decreases PD-L1 expression on the cell surface, while dual targeting of CMTM6 and CMTM7 significantly reduces PD-L1 expression (Xiao et al., 2021), suggesting that CMTM-targeted molecular therapy can improve the prognosis of breast cancer patients.